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Since anti-HIV treatment cannot cure the infection, many strategies have been proposed
to eradicate the viral reservoir, which still remains as a major challenge. The success of
some of these strategies will rely on the ability of HIV-specific CD8+ T-cells (CD8TC)
to clear reactivated infected cells. Here, we aimed to investigate the phenotype and
function of in vitro expanded CD8TC obtained from HIV+ subjects on combination
antiretroviral therapy (cART), either initiated earlier (median = 3 months postinfection,
ET: Early treatment) or later (median = 20 months postinfection, DT: Delayed treatment)
after infection. Peripheral blood mononuclear cells from 12 DT and 13 ET subjects
were obtained and stimulated with Nef and Gag peptide pools plus IL-2 for 14 days.
ELISPOT was performed pre- and post-expansion. CD8TC memory/effector phenotype,
PD-1 expression, polyfunctionality (CD107a/b, IFN-γ, IL-2, CCL4 (MIP-1β), and/or
TNF-α production) and antiviral activity were evaluated post-expansion. Magnitude
of ELISPOT responses increased after expansion by 103 times, in both groups.
Expanded cells were highly polyfunctional, regardless of time of cART initiation.
The memory/effector phenotype distribution was sharply skewed toward an effector
phenotype after expansion in both groups although ET subjects showed significantly
higher proportions of stem-cell and central memory CD8TCs. PD-1 expression was
clustered in HIV-specific effector memory CD8TCs, subset that also showed the highest
proportion of cytokine–producing cells. Moreover, PD-1 expression directly correlated
with CD8TC functionality. Expanded CD8TCs from DT and ET subjects were highly
capable of mediating antiviral activity, measured by two different assays. Antiviral function
directly correlated with the proportion of fully differentiated effector cells (viral inhibition
assay) as well as with CD8TC polyfunctionality and PD-1 expression (VITAL assay). In
sum, we show that, despite being dampened in subjects on cART, the HIV-specific
CD8TC response could be selectively stimulated and expanded in vitro, presenting a high
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proportion of cells able to carry-out multiple effector functions. Timing of cART initiation
had an impact on the memory/effector differentiation phenotype, most likely reflecting
how different periods of antigen persistence affected immune function. Overall, these
results have important implications for the design and evaluation of strategies aimed at
modulating CD8TCs to achieve the HIV functional cure.
Keywords: HIV functional cure, expanded CD8+ T-cell response, polyfunctionality and phenotype, antiviral activity,
time of cART initiation
INTRODUCTION
Infection with Human Immunodeficiency Virus (HIV) causes an
irreversible and profound deterioration of the immune system
as well as abrogated T cell homeostasis, ultimately leading to the
development of acquired immunodeficiency syndrome (AIDS) in
the vast majority of infected persons. Despite dramatic advances
made over the past three decades, it still constitutes a major
public health concern worldwide. Following virus transmission,
acute/early phase of infection is characterized by a high-level
peak of viremia, rapid loss of CD4+ T-cells in both peripheral
blood and mucosal lymphoid tissues, and clinical symptoms (1–
3). Emergence of HIV-specific CD8+ T-cell response is associated
with the drop of plasma viremia to a stable level, known as the
viral set-point (4).
Since the implementation of combination antiretroviral
therapy (cART), AIDS-associated death rates have decreased
drastically, and morbidity and mortality of HIV+ subjects have
been considerably reduced (with a concomitant improvement in
their quality of life). Besides, transmission risks have diminished
(with an impact on the global epidemic dynamics) (5). cART
can quickly and persistently suppress viral replication but, if
treatment is interrupted, plasma viral load (VL) rapidly increases
(6, 7). The failure to eradicate HIV infection is due to the
intrinsic stability of the viral genome in latently infected CD4+
T-cells and also other long-lived cells (8). Consequently, cART
is currently a lifelong treatment with some limitations: the need
of daily doses, the development of viral resistance, toxicity,
and the impossibility to clear the infection. Moreover, even
effectively treated HIV-infected individuals have a greater risk of
experiencing non-AIDS related morbidity and mortality events
than age-matched HIV-uninfected adults (including accelerated
immune aging, higher cardiovascular risk, coagulopathies and
other metabolic disorders), indicating that even effective cART
cannot fully restore health (9). In this line, the idea of developing
a cure for HIV infection has gained intense interest over the last
years; this is the development of a therapeutic intervention or
approach that controls (functional cure or long-term remission
in the absence of cART) or eliminates (sterilizing cure) HIV
infection (3, 10). To pursue this objective, several strategies are
being investigated as reviewed in Deeks et al. (3) and Pitman
et al. (11). Many of these strategies, such as the “shock and kill”
model, require the preexistence of cellular responses being able to
actively clear reactivated and/or persistent virus. However, CD8+
T-cell responses are severely waned in subjects on cART, limiting
thus these approaches (12).
During the natural course of infection, HIV-specific CD8+
T-cells play a central role in the control of viral replication,
particularly during acute infection (2, 4, 12). In this setting,
our group has provided evidence regarding different qualitative
aspects of the response (specificity, functionality, and phenotype)
that better associate with virus control in an acute infection
cohort from Argentina (13, 14). Progressive infection is
characterized by the presence of a narrow, oligofunctional
and exhausted cellular response. As subjects initiate cART, the
magnitude of the CD8+ T-cell response declines rapidly (15–20)
though some publications have demonstrated that the remaining
cells still possess antiviral functions (21–23). Importantly, it has
been recently illustrated in a non-human primate model that
CD8+ T-cells might have a role in controlling viral production
even on cART (24). Moreover, some studies have indicated
that CD8+ T-cells still exert selective pressure in subjects on
cART, suggesting that this response might be acting on viral
residual replication as reviewed in McIlroy (25). Finally, different
attributes of the CD8+ T-cell response have been related to
the reservoir size once the subjects are on treatment (26–
30). However, cART interruption leads to rapid viral rebound,
indicating that control mediated by CD8+ T-cells is temporal and
inefficient (31).
Thus, the success of the strategies aimed at eliminating the
viral reservoir using HIV-specific memory CD8+ T-cells that
persist after cART initiation will require refined knowledge about
the functional and phenotypic properties of these cells. Here,
we aimed to investigate the phenotype and function of in vitro
expanded CD8+ T-cells from HIV+ subjects on cART who
initiated treatment either early or late after infection. Results
indicated that HIV-specific cells can be selectively stimulated
and expanded in vitro, presenting a high proportion of cells
able to carry out multiple effector functions. On the contrary,
cART initiation timing had an impact on the memory/effector
differentiation phenotype. Despite this, expanded cells from
both groups had potent antiviral activity. Thus, we propose
that despite differences in the duration of antigen persistence,
HIV-specific CD8+ T-cells remain detectable and functional but
should be boosted in order to support viral clearance.
MATERIALS AND METHODS
Study Subjects
Twenty-five HIV+ subjects were enrolled during acute/early
infection and followed up longitudinally as part of the Grupo
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Argentino de Seroconversión study group. Enrollment criteria
were described elsewhere (32, 33). Twelve subjects initiated cART
after 4 months since the estimated date of infection (from now on
Delayed Treatment (DT) group), and 13 initiated cART within
4 months post-infection (Early Treatment group, ET). For this
study, samples were collected from study participants at ∼12
months post-cART initiation.
This study was reviewed and approved by two institutional
review boards: Comité de Bioética Humana, Fundación Huésped,
and Comité de Ética Humana, Facultad de Medicina, Universidad
de Buenos Aires, Buenos Aires, Argentina. All participants
provided written informed consents and agreed to participate in
this study in line with the Declaration of Helsinki.
Samples
Forty ml of whole blood were collected from study participants,
centrifuged to separate plasma, and stored at −80◦C. Peripheral
blood mononuclear cells (PBMCs) were isolated by Ficoll-
Hypaque density gradient centrifugation (Amersham, Sweden)
and cryopreserved for subsequent functional assays. Plasma
viral load (VL) was determined by branched-DNA, Versant
HIV-1 RNA 3.0 assay (Siemens Healthcare, UK). CD4+ and
CD8+ T-cell counts were determined using TruCount absolute-
count tubes (BD Bioscences, USA) on a BD FACSCalibur flow
cytometer.
Peptide Pools
Potential T-cell epitope (PTE) peptide panels corresponding to
Nef (unique pool, n = 127 peptides) and Gag [2 pools: p17 (n =
97) and p24 (n = 128)] HIV proteins and the cytomegalovirus
(CMV), Epstein-Barr virus, and influenza virus (CEF) peptide
pool were obtained from the NIH AIDS Reagent Program (34,
35). Lyophilized peptides were dissolved in dimethyl sulfoxide
(DMSO) at 40 µg/µl and stored at−20◦C.
HIV-Specific CD8+ T-Cell Expansion
Cryopreserved PBMCs were thawed in PBS (Sigma-Aldrich),
2% fetal bovine serum [FBS; Gibco BRL], and 1mM EDTA
supplemented with 25 U/ml DNase I (Benzonase nuclease;
Sigma-Aldrich) and then rested overnight (ON) in DNase-free
complete RPMI medium (RPMIc; RPMI 1640 [Gibco BRL], 10%
fetal bovine serum [FBS; Gibco BRL], 2mM L-glutamine [Gibco
BRL], 100 U/ml penicillin [Gibco BRL], 100µg/ml streptomycin
[Gibco BRL], 10mM HEPES [Gibco BRL]). Rested PBMCs were
cultured in 12-well plates at a density of 2–3 × 106 cells/ml in
cRPMI medium supplemented with 100 U/ml IL-2 (Biolegend
Inc, USA) and in the presence of 1µg/ml of the corresponding
HIV peptide pool or CEF peptide pools, for 14 days. Mediumwas
replaced every 72 h with freshly-prepared cRPMI supplemented
with IL-2. Expanded cells were subsequently studied by ELISPOT,
flow cytometry, and antiviral activity assays (Figure 1).
ELISPOT Assay
Interferon gamma (IFN-γ)-secreting cells were evaluated by
ELISPOT before and after HIV-specific CD8+ T-cell expansion
(pre-expansion, i.e., immediately after PBMC ON rest, and post-
expansion) following the protocols published previously (13, 36,
37).
Flow Cytometry
CD8+ T-cell phenotype and functionality were evaluated in
14-day expanded cells by flow cytometry as reported by
our group, with modifications (13, 14, 38). Briefly, cells
were re-stimulated with the designated peptide pool (same
used for expansion, at 2µg/ml) or DMSO (to account for
background) plus costimulatory antibodies (anti-CD28 and
anti-CD49d; 1µg/ml; BD Biosciences), monensin (Golgistop,
0.7 µl/ml; BD Biosciences) and brefeldin A (10µg/ml; BD
Biosciences) for 5 h at 37◦C. Anti-CD107a/b-FITC antibodies
(BD Biosciences) were also added to identify degranulating
cells. For the functionality panel, cells were stained upon
stimulation with Zombie NIRTM Fixable Viability Kit (Biolegend,
USA), and the following conjugated antibodies: anti-CD14-V450,
anti-CD19-V450, anti-CD3-BV786, anti-CD8-APC, and anti-
CD4-BV650 (BD Biosciences). Then, cells were permeabilized
(Permeabilization Wash Buffer, Biolegend), fixed (Fixation
Buffer, Biolegend), and subsequently stained using anti-IL-2–
PerCP-Cy5.5, anti-TNF-α-PECy7, anti-IFN-γ-BV711, and anti-
CCL4-PE conjugated antibodies (BD Biosciences).
In parallel, CD8+ T-cell memory phenotype was studied.
Cells were shortly stimulated as described above and afterwards
stained with Zombie NIRTM Fixable Viability Kit plus the
following conjugated antibodies: anti-CCR7-Alexa700, anti-PD-
1-PE, anti-CD3-BV786, anti-CD8-APC, anti-CD4-BV650, anti-
CD14-V450, anti-CD19-V450, anti-CD45RO-PerCPCy5.5, and
anti-CD95-PE-CF594 (BD Biosciences, USA). Then, cells were
permeabilized, fixed and stained with anti-IL-2, anti-TNF-α,
and anti-IFN-γ antibodies, all of them conjugated to FITC (BD
Biosciences) to identify specific cells regardless of its function.
Flow cytometry data acquisition was performed on a 3-laser
14-color BD FACSAria FUSION flow cytometer using the BD
FACSDiva v 8.0.1 software (BD Biosciences). Instrument settings
and fluorescence compensation were performed using unstained
samples and single stained BD CompBeads (BD Bioscience).
Isotype controls, consisting of expanded, stimulated cells stained
with conjugated antibodies to CD14, CD19, CD3, CD4, and
CD8 surface molecules plus the isotype controls corresponding
to the CCR7, CD45RO, CD95, PD-1, and/or the corresponding
intracellular marker staining, were performed for each individual
in order to set negative populations accurately.
Acquired data was analyzed using FlowJo v10 (Data Analysis
Software, LLC). Gating strategy was performed as shown in
Figure S1. First, single cells were selected in a forward scatter
area (FSC-A) vs. FSC-Height plot. Then, dead cells were excluded
on the bases of Zombie NIR
TM
fluorescence and monocytes
as well as B lymphocytes were also excluded on the bases of
V450 fluorescence (CD14 and CD19 staining). Subsequently,
the lymphocyte population was selected in a FSC-A vs. side
scatter (SSC) plot. Samples with at least 100,000 events in the
lymphocyte gate were included in subsequent analyses. Finally,
CD3+ CD8+ (or CD4+) cells were gated in CD3-vs.-CD8 (or
CD4) dot plots.
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FIGURE 1 | Schematic representation of the experimental design. PBMC samples were obtained from enrolled subjects. First, IFN-γ ELISPOT was performed
directly ex vivo (pre-expansion). PBMCs were then expanded for 14 days in the presence of Nef or p24 peptide pool, generating Nef-specific and p24-specific
effector. At day 14, IFN-γ ELISPOT, CD8+ T-cell polyfunctionality and CD8+ T-cell phenotype (CCR7, CD45RO, CD95, and PD-1) were evaluated by flow cytometry.
Expanded CD8+ T-cells were also purified and used as effectors in the VIA (1) and VITAL (2) assays. In parallel, autologous CD4+ T-cells were purified with CD3.8
bispecific antibodies to generate CD4+ target cells. See M&M for further details. PBMC, Peripheral blood mononuclear cells; VIA, Viral inhibition assay; CTL, CD8+
T-lymphocyte.
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To study CD8+ T-cell polyfunctionality, CD8 vs. CD107a/b,
IFN-γ, IL-2, CCL4, or TNF-α plots were constructed. After
the gates for each function were created, the Boolean gate
platform was used to create the full array of obtainable
combinations, equating to 32 possible combinations. Data
presented correspond to background-subtracted results using the
DMSO plus CD28/CD49d stimulation. This was performed on
a cytokine-subset-by-cytokine-subset basis, i.e., subtracting the
result from this condition for a given cytokine subset to the same
subset of a peptide-stimulated condition. One standard deviation
(SDs) above background was set as the threshold for determining
positive responses. Values below this threshold were set at 0.
For phenotype analysis, HIV-specific CD8+ T-cells were
identified in a CD8 vs. FITC plot (CD107a/b, IFN-γ, IL-2,
CCL4, and TNF-α). A positive cytokine response was defined
as at least twice the background value, >0.05% after subtraction
of background and at least 1,000 events. This criterion was
established to minimize the possibility of error due to a low
number of events when further subdividing these cells into the
different memory subsets. To analyze the distribution of the
different phenotype subsets, CD45RO vs. CCR7 density plots
were constructed on both bulk and HIV-specific CD8+ T-cells
to identify central memory T-cells (TCM, CCR7
+/CD45RO+),
effector memory T-cells (TEM, CCR7
−/CD45RO+), and terminal
effector T-cells (TTE, CCR7
−/CD45RO−). CD95 expression was
analyzed within the CD45RO−CCR7+ cells thus defining naïve
T-cells (TN, CCR7
+/CD45RO−/CD95−) and stem-cell memory
T-cells (TSCM, CCR7
+/CD45RO−/CD95+). Additionally, PD-1
expression was studied both on bulk (total and also within each
memory subpopulations) and HIV-specific CD8+ T-cells.
CD8+ T-Cell Antiviral Activity
Antiviral activity of expanded CD8+ T-cells was evaluated by
two different assays (Figure 1): The Viral Inhibition Assay [VIA,
(13, 39, 40)] and the VITAL assay [adapted from Hermans
et al. (41)]. In the former, both cytolitic and non-cytolitic
mechanisms of viral inhibition are accounted while in the latter
direct cell-mediated toxicity is measured. For both assays, target
(autologous CD4+ T-cells) and effector (expanded CD8+ T-cells)
were prepared following the same procedure:
Generation and Isolation of Expanded Nef- and
p24-Specific Effector CD8+ T-Cells
PBMCs were thawed and stimulated with either peptide pools
spanning Nef or p24 proteins as stated above (day 0). At
day 13 post-expansion and after a 5-h short re-stimulation
(as described previously), percentages of cytokine-producing
cells and degranulating cells (i.e., total HIV-specific cells) were
assessed by flow cytometry. At day 14, expanded CD8+ T-
cells were isolated by positive selection using Anti-Human CD8
Magnetic Particles (BD Biosciences).
Generation of Autologous CD4+ T-Cell Targets
PBMCs were thawed and cultured in cRPMI medium
supplemented with 50 U/ml IL-2 plus 0.5µg/ml CD3/8 bi-
specific antibody (obtained through the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH: Anti-Human CD3/8
Bi-specific Monoclonal from Drs. Johnson Wong and Galit
Alter). PBMC treatment with CD3/8 bi-specific antibody results
in the elimination of CD8+ T-cells and purification of activated
CD4+ T-cells. To determine purity, expanded CD4+ T-cell were
stained with Zombie viability kit, anti-CD3-PECy7, anti-CD4-
PerCP, and anti-CD8-BV510 at day 13. In all cases, 90% purity
was achieved.
Viral Inhibition Assay (VIA) (Figure 1)
Target cells (purified and activated CD4+ T-cells) were infected
in parallel with 4 different viral strains: an X4-tropic laboratory
strain (NL4-3) and three HIV-1 clade B transmitted/founder
(T/F) primary viruses selected from the full panel of T/F
Infectious Molecular Clones available at the NIH AIDS Reagent
program (Division of AIDS, NIAID, NIH: Cat #11742 (X4-tropic
T/F virus, from now on Virus 4, V4), cat #11746 (R5-tropic
T/F virus obtained after an event of heterosexual transmission,
from now on Virus 8, V8), and Cat #11749 (R5-tropic T/F
virus obtained after an event of male-to-male transmission,
from now on Virus 9, V9) from Dr. John Kappes (42–45).
Pseudotyped viral stocks were produced by co-transfecting 293T
cells with the corresponding HIV plasmid together with a
plasmid encoding the Vesicular Stomatitis Virus (VSV) protein
G, using the X-treme GENE 9 DNA transfection reagent (Roche,
Switzerland). Culture supernatants were harvested 48 h post-
transfection clarified by centrifugation at 600 g for 15min at
4◦C, fractioned and stored at −80◦C until use. Viral titer was
estimated by p24 antigen quantitation by ELISA (Sino Biological
Inc., China).
Viruses were added to target cells at 15 ng p24/100,000 CD4+
T-cells. In order to improve infection efficiency, plates were first
centrifuged at 1,200 g for 1 h at 22◦C (spinoculation), and then
viral adsorption was let to proceed for an extra hour at 37◦C in
a humidified CO2 incubator. After infection, cells were washed
twice and co-cultured at 1:1 ratio with purified expanded Nef-
specific or p24-specific CD8+ T-cells (effectors) in U-bottom
96-well plates, in cRPMI medium containing 10 U/ml IL-2.
Infectivity controls consisted of infected CD4+ T-cell targets
without CD8+ T-cell effectors. Uninfected controls consisted
of uninfected target cells without effectors. All conditions were
assayed in triplicate. At day 4 post-infection, half of the culture
supernatant was removed and replenished with fresh medium.
At day 7, supernatants were collected and stored at −20◦C
until p24 antigen quantitation by ELISA. CD8+ T-cell anti-HIV
suppressive capacity was calculated as the log10 of the percentage
of p24 antigen loss when CD8+ T-cells were present in the culture
compared to CD4+ T-cell infected controls without effectors, for
each virus.
In vitro Cell Killing Assay (VITAL Assay, Figure 1)
2 × 106 cells/ml target cells (purified and activated CD4+ T-
cells) were first stained with 1µM of CFSE (Molecular Probes,
USA) at 37◦C for 8min, followed by the addition of an equal
volume of FBS to quench the reaction. After CFSE staining,
cells were loaded with peptide antigens by incubation for 2 h
in cRPMI supplemented with 2µg/ml of either Nef or p24
peptide pool. In parallel, untreated CD4+ T-cells (i.e., not loaded
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with peptides) were labeled with 2µM PKH26 red fluorescent
cell linker (Sigma-Aldrich, USA). Peptide-loaded CFSE+ and
unloaded PKH26+ cells were extensively washed, combined and
plated in U-bottomed 96-well plates at 5 × 104 cells of each
fluorescent population per well. Nef- or p24-specific effector cells
were added to the corresponding wells at the indicated target-
to-effector (T:E) ratios (1:1, 1:5, 1:10 and 1:1 adjusted [i.e., 1:1
ratio adjusted to proportion of specific CD8+ T-cell effectors
as determined by intracellular staining and flow cytometry]),
in triplicate. Following overnight incubation at 37◦C, cells were
stained with Zombie Viability Kit and anti-CD3-PECy7, anti-
CD4-PerCP, and anti-CD8-BV510 antibodies, and analyzed in a
2-laser, 8-color BD FACSCanto flow cytometer. Data acquisition
was performed using the BD FACSDiva software and analyzed
subsequently with FlowJo v10 software (Data Analysis Software,
LLC). Initial gating was performed in a FSC-A vs. FSC-H plot
to exclude doublets, and then lymphocytes were selected in a
FSC-H vs. SSC-A plot. Subsequently, Zombie- negative cells (i.e.,
living cells) were gated. Then, CD3+CD4+ cells were selected and
the analysis was performed on this population. CFSE vs. PKH26
plots were constructed, and cell survival of antigen-loaded targets
cells (CFSE-positive) in the presence of effectors was determined
compared to conditions without effector cells. Adjusted survival
was calculated as the mean percentage of CFSE+ events with
added effector vs. the condition with no effectors. Finally, the
percentage of specific lysis was calculated using the equation:
%specific lysis: 100—%adjusted survival.
Data Analysis
The presumed date of infection was estimated as reported
previously (32, 33). Date of cART initiation was informed by
clinicians. Most data was expressed as median values with
interquartile ranges (25 to 75%, IQ25-75) and analyzed by
nonparametric methods using GraphPad Prism 7 software,
unless otherwise stated. Inter- and intra-group comparisons
were performed using Mann-Whitney and Wilcoxon tests,
respectively. Correlation analyses were performed using the
Spearman’s rank test. In this case, p-values were adjusted
for multiple comparisons using a false discovery rate (FDR)
procedure, according to the Benjamini and Hochberg method,
using the GraphPad Prism 7 software.
For the polyfunctionality analysis and cell phenotype data
sets generated by flow cytometry, SPICE 6.0 software (https://
niaid.github.io/spice/) was used following the experimental and
technical considerations published by the software developers
(46). In particular, Student’s t-test and a partial permutation test
were used to compare distribution profiles between groups.
All tests were considered significant when the p-value
was <0.05. Adjusted p-values for correlation analyses were
considered significant when <0.1.
RESULTS
Study Subjects
Twenty-five HIV+ subjects were enrolled during acute/early HIV
infection (within 6 months from presumed date of infection)
and followed up for over at least 1 year after cART initiation.
Subjects were segregated into two subgroups according to cART
initiation timing. A 4-month post-presumed date of infection
cut-off was selected based on the fact that CD8+ T-cells are key
players in viral set point establishment, which is usually reached
around 4 months post-infection (2, 47). Thus, the responses
evaluated would represent pre- and post-set-point scenarios.
Delayed Treatment group (DT; 12 subjects) included subjects
who initiated treatment after 4 months from presumed date
of infection (median time to cART initiation = 20 months,
[Interquartile range IQ25-75: 9.5–24.25 months]) while Early
Treatment group (ET; 13 subjects) included subjects who started
cART within 4 months post-presumed date of infection (median
time to cART initiation = 3 months [IQ 25–75: 2–3.5 months]).
All samples used for the study were obtained at ∼1 year after
treatment initiation (DT: median time on cART = 13 months
[IQ25-75: 5.75–18 months]; ET: median = 14 months [IQ25-
75: 12–16.5 months]). Detailed descriptions of participants are
shown in Table 1.
Median pre-treatment plasma VL was significantly higher in
ET compared to DT (283,441 RNA copies [IQ25-75: 31,443–
500,000] and 38,407 RNA copies/ml [IQ 25-75: 11,349–122,260],
respectively; p= 0.0207). This reflects the fact that DT individuals
already reached the VL set point by the moment of cART
initiation while ET individuals had not reached that stage yet. All
samples obtained after cART initiation and used for this study
had undetectable plasma VL (lower limit of detection 50 RNA
copies/ml).
Pre-treatment CD4+ T-cell counts and CD4/CD8 ratios did
not differ between groups (DT: median CD4+ T-cell count
= 370 cells/µl [IQ25-75: 290.3–450.8], Median CD4/CD8 ratio
= 0.45 [IQ25-75: 0.33–0.66]. ET: median CD4+ T-cell count =
435 cells/µl [IQ25-75: 334.5–640.5], Median CD4/CD8 ratio=
0.33 [IQ25-75: 0.18–0.68]). Both groups experienced significant
improvements in both parameters by 1 year after cART initiation
compared to the pre-cART determination (DT: median CD4+ T-
cell count=549 cells/µl [IQ25-75: 506.8–732], p= 0.002; median
CD4/CD8 ratio = 0.755 [IQ25-75: 0.67–1.26], p = 0.0005; ET:
median CD4+ T-cell count= 829 cells/µl [IQ25-75: 625.5–1053],
p= 0.0005; median CD4/CD8 ratio= 1.32 [IQ25-75: 0.89–1.74],
p = 0.0002). Moreover, both CD4+ T-cell count and CD4/CD8
ratio evaluated on-cART were significantly higher in ET vs. DT
(p= 0.025 and p= 0.014, respectively), mirroring a poorer CD4+
T-cell recovery in DT after a longer period prior cART initiation.
HIV-Specific T-Cells From DT and ET
Subjects on cART Could Be Equally
Expanded in vitro
Based on the notion that HIV-specific CD8+ T-cell frequency
decays significantly following cART initiation, and that the
median half-life for the rate of decay is around 40 weeks (16),
we first evaluated whether HIV-specific CD8+ T-cells from DT
and ET subjects after 1 year of cART could be expanded in
an in vitro model. For this, PBMCs were stimulated with HIV
peptide pools spanning Nef and Gag (sum of anti-p24 and p17
responses) proteins or the control CEF pool; plus IL-2 for 14 days
and specific responses were evaluated pre- and post-expansion by
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TABLE 1 | Clinical data corresponding to HIV+ subjects enrolled per study group.
CD4 count CD4/CD8
IDa Time to cART
(months)b
Time on cART
(months)c
Pre-treatment
Viral Loadd,e
Before
cARTd,f
On cARTf,g Before
cARTd,f
On cARTf,g
DT1 50 22 48526 383 524 0.72 1.35
DT2 22 18 132317 324 297 0.46 0.52
DT3 8 18 125716 391 711 0.48 0.65
DT4 11 5 27244 465 535 0.45 0.74
DT5 25 5 4612 408 739 0.48 1.00
DT6 19 15 66929 246 501 0.24 0.62
DT7 50 5 15297 330 468 0.42 0.77
DT8 5 12 >500000 279 528 0.26 0.72
DT9 21 14 28288 184 579 0.30 0.88
DT10 13 20 1702 357 563 0.44 0.72
DT11 22* 12 10033 819 819 0.88 1.36
DT12 9 8 111893 629 880 0.85 1.53
ET1 2 14 >500000 627 594 0.66 0.89
ET2 4 18 283441 187 522 0.20 0.88
ET3 1 11 36338 768 1099 1.18 1.83
ET4 3 14 17292 612 1342 0.33 1.32
ET5 3 15 20106 787 829 1.06 1.69
ET6 2 18 >500000 421 854 0.31 1.89
ET7 1 13 >500000 435 942 0.13 1.52
ET8 3 12 172468 435 657 0.59 1.16
ET9 3 17 26547 400 728 0.70 1.79
ET10 3* 11 231360 330 1080 0.18 1.24
ET11 2 12 >500000 654 1026 0.42 1.47
ET12 4 16 >500000 339 691 0.08 0.66
ET13 4 12 >500000 213 386 0.19 0.81
aDT, Delayed Treatment Group; ET, Early Treatment Group.
bRelative to the presumed date of infection.
cTime from the moment of cART initiation to sample obtaining.
dDeterminations evaluated at the closest sample obtained before cART initiation.
eVersant HIV-1 RNA 3.0 assay, Siemens. Lower and upper detection limits are 50 and 500,000 RNA copies/ml, respectively (1.7 and 5.7 log10 ).
fDetermined by flow cytometry.
gDeterminations evaluated in samples used in this study.
*Estimated time to cART initiation, as informed by the clinician.
ELISPOT (Figure 2A). Median pre-expansion responses found
in DT were 30 SFU/106 PBMC (IQ25-75 25–65) for Nef, 107.5
(58.75–257.5) for Gag and 147.5 (51.25–366.3) for CEF peptides.
No significant differences were found when comparing pre-
expansion DT responses with those evaluated in ET, which were
as follows: 25 (25–55) for Nef, 40 (25–346.3) for Gag, and
117.5 (25–495) for CEF peptides. After expansion, responses
to all antigens tested were significantly increased in both study
groups (by 103 times) and were predominantly mediated by
CD8+ T-cells, as observed later by flow cytometry (as explained
below) which is consistent with higher representation of MHC-
class I restricted peptides within the PTE peptide pools. Post-
expansion magnitude in DT was 9,390 SFU/106 PBMC (IQ25–
75 2,800–255,455) for Nef (p = 0.0039, compared to the pre-
expansion condition), 7,700 (3,415–507,893) for Gag (p =
0.002) and 253,155 (617.5–500,000) for CEF (p = 0.0176).
Similarly, post-expansion magnitude in ET was 2,110 (441.3–
5,900) for Nef (p = 0.0005), 3,105 (1,365–4,578) for Gag (p
= 0.0005) and 8,740 (940–500,000) for CEF (p = 0.0005). No
differences were observed between DT and ET, for any of the
antigen used. Then, the relative contribution of each antigen
to the total post-expansion anti-HIV response was analyzed
to provide an image of the response breadth for both groups
(Figure 2B). DT individuals showed an even contribution of
anti-Nef, p17 and p24 responses to the total HIV response.
Although the distribution was not different fromET (p= 0.1786),
it is worth highlighting that ET showed a lower contribution
of anti-p17 responses and a higher contribution of anti-Nef
responses, resulting globally in a narrower response mostly
directed toward Nef and p24. Moreover, no differences were
found when comparing the pre- and post-expansion distribution
intragroups (not shown). Finally, themean spot size was recorded
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in both pre- and post-expansion conditions as a measure of
the amount of IFN-γ produced by the individual specific T-
cells (Figure 2C). Mean spot size significantly increased after
expansion with all antigens tested. No significant differences
were observed between DT and ET subjects. In sum, the
magnitude of HIV-specific cellular responses could be equally
expanded in vitro both in DT and ET subjects, and cells showed
higher potential to secrete IFN-γ after stimulation. Of note, this
parameter has been associated with higher T-cell avidity and a
polyfunctional profile (13, 48, 49). Finally, DT subjects displayed
a broader response to HIV peptide pools after expansion than ET
subjects.
Polyfunctionality of Expanded CD8+
T-Cells Is Not Conditioned by cART
Initiation Timing
T-cell polyfunctionality has been largely considered an important
metric reflecting the quality of the T-cell response (50). Thus,
the capacity to degranulate (evaluated by the mobilization of
CD107a/b to the plasma membrane) and to produce IFN-γ, IL-
2, CCL4 (MIP-1β), and TNF-α was evaluated post-expansion
by flow cytometry (gating strategy is shown in Figure S1).
From this point forward, only CD8+ T-cells expanded with Nef
and p24 peptide pools were analyzed. p17-specific cells were
excluded because, in this model, they proved limited expansion
potential. It was observed that, as aforementioned, CD8+ T-
cells were preferentially expanded in our model, and CD4+ T-
cells represented only a small proportion of cells after expansion
(data not shown). When analyzing CD8+ T-cells expressing
each of the functions either alone or in combination, and in
consonance with the ELISPOT results, it was first noted that
the proportion of responsive cells was much higher than that
found when evaluating this parameter directly ex vivo (13,
14, 51). This finding is in line with the specific proliferation
and survival of HIV-specific cells after the in vitro expansion.
No significant differences were observed between DT and ET
subjects either when polyfunctionality was analyzed as a whole
or when functions were analyzed individually or combined
(Figure 3A). Then, the same analysis was performed but splitting
the responses toward the different HIV antigens and CEF
(Figure 3B). In this case, total proportion of mono, bi, tri,
tetra, and pentafunctional cells were analyzed independently
of any particular function due to the low number of positive
responses when fragmenting the analysis. By doing this, no
differences were observed in the polyfunctional profile of
expanded Nef-specific, p24-specific, even in CEF-specific CD8+
T-cells obtained from ET. Only a non-significant reduction in
the proportion of pentafunctional Nef-specific and p24-specific
cells was observed when compared to CEF-specific cells from
the same group. Conversely, expanded p24-specific CD8+ T-cells
from DT subjects showed an enrichment of monofunctional cells
compared to Nef-specific (p= 0.042) and CEF-specific (p= 0.16)
cells. Overall, expanded HIV-specific CD8+ T-cells from DT
and ET subjects showed a polyfunctional response comparable
to CEF-specific responses, with high proportions of tetra and
pentafunctional cells.
Time to cART Initiation Impacts on CD8+
T-Cell Memory/Effector Phenotype
Distribution Post-expansion
Cell phenotype was then evaluated by flow cytometry
(Figure S1). Distribution of naïve (TN), stem-cell memory
(TSCM), central memory (TCM), effector memory (TEM),
and terminal effector (TTE) T-cells was studied both on
bulk and HIV-specific CD8+ T-cells. In addition, expression
of PD-1 was monitored. As expected, the general memory
phenotype distribution was sharply skewed toward an
effector phenotype after expansion. When analyzing the
distribution of memory phenotype within the bulk CD8+ T-cell
compartment, the following hierarchy emerged in both groups:
TTE >TEM >TSCM >TCM >TN (Figure 4A). However, the
global distribution was significantly different between DT and ET
(p = 0.0051) driven by intergroup differences in the proportion
of various sub-populations: ET subjects showed significantly
higher proportions of TSCM (median % 11.93 vs. 4.21, p =
0.003) and TCM (median % 1.9 vs. 1.00, p = 0.016) subsets,
and significantly lower proportions of TTE (median % 44.35 vs.
73.70, p= 0.003). Percentages of TN cells were minimum in both
groups (0.22 and 0.64% in DT and ET, respectively). Within the
HIV-specific compartment, TEM and TTE were exclusively found
among cells from DT while in ET subjects TSCM and TCM were
also observed. The same pattern was observed for Nef-specific
and p24-specific responses as well as for the CEF-specific
response when analyzed separately (Figure 4B). In this case,
the differences observed were not statistically significant, most
likely due to the reduced numbers of positive responses when the
analysis was segregated across antigens.
Then, we sought to analyze PD-1 expression in expanded cells.
First, it was observed that the PD-1 expression was markedly
lower in expanded cells compared to previous studies in a similar
population but measuring PD-1 expression directly ex vivo (not
shown) (14, 52–54). No significant differences were observed
in PD-1 expression either at the bulk or HIV-specific CD8+ T-
cells compartments, between DT and ET groups (Figure 5A).
On the other hand, HIV-specific cells showed significantly
higher PD-1 expression compared to the bulk compartment,
both in DT (p = 0.0268) and ET (p < 0.0001) which is in
consonance with previous observations in other settings (14,
55, 56). Then, the distribution of different memory/effector
phenotypes was investigated within the PD-1+ events (only
for the bulk compartment) (Figure 5B). The global distribution
of subsets was significantly different between groups (p =
0.0339), with DT subjects showing an increased representation
of CD8+ TTE cells within the PD-1
+ events, compared to ET
subjects (p = 0.026) who, in turn, showed higher proportions
of TSCM and TCM CD8
+ PD-1+ cells (p = 0.023 and p =
0.013, respectively). Subsequently, we aimed to analyze the PD-
1 expression distribution along the different memory/effector
phenotypes. Due to the reduced number of events within the TN,
TSCM, and TCM subsets, this analysis could only be performed on
the bulk CD8+ TEM and TTE subsets. In both DT and ET subjects,
PD-1 expression was significantly higher in TEM compared to
TTE subsets (Figure S2A). Likewise, TEM CD8
+ cells showed a
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FIGURE 2 | ELISPOT screening of HIV-specific T-cell response before and after in vitro expansion, in samples from DT and ET individuals obtained after one year on
cART. (A) Magnitude of total anti-Nef, anti-Gag (sum of anti-p17 and anti-p24 responses), and anti-CEF IFN-γ-producing cellular responses, expressed as spot
forming units (SFU)/106 PBMCs, measured pre- and post-expansion in vitro on a subject-by-subject basis (each represented by a line). (B) Relative contribution of
each antigen to the total HIV post-expansion response expressed as the percentage out of the total sum of the specific response (sum of the magnitude obtained for
all Nef, p17 and p24 antigens), for DT (left pie) and ET (right pie) subjects. (C) Mean spot size obtained for HIV and CEF peptide pools at pre- and post-expansion
conditions. HIV mean spot sizes represent the average mean spot sizes out of all Nef, Gag, and CEF pools for which a positive response was obtained in the ELISPOT
assay on a subject-by-subject basis. Intragroup differences were analyzed using Wilcoxon test. Asterisks denote different P values: *p < 0.05; **p < 0.01; ***p <
0.005. DT, Delayed treatment (N = 10); ET, Early treatment (N = 13).
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FIGURE 3 | CD8+ T-cell polyfunctionality analysis after in vitro expansion with specific peptides. (A) Pies depict the distribution of mono-(blue), bi-(green), tri-(yellow),
tetra-(orange), and penta-functional (red) cells within HIV specific CD8+ T-cells, for DT and ET subjects. Bar charts represent the proportion of HIV-specific CD8+
T-cells displaying each particular function or combination of functions (31 possible combinations of positive responses). The color code shown at the bottom mirrors
the one shown in the pies. Black dots represent DT subjects and gray dots represent ET subjects. Boxes extend from min to max, horizontal bar within boxes
represent median values (B) Polyfunctional profile for CD8+ T-cells with different specificities (Nef, p24 or CEF) within DT group (left panel) and ET group (right panel).
This analysis was performed considering cells that were able to mediate either one, two, three, four, or five functions, regardless of any particular function or function
combination (block analysis). Analyses were performed with SPICE software. When analyzing global distribution (pies) permutation tests were applied, instead when
analyzing bar graphs, Student T-test were used. *p < 0.05. DT, Delayed treatment (N = 11 for Nef- and p24-specific responses, N = 8 for CEF-specific responses);
ET, Early treatment (N = 12 for Nef- and p24-specific responses, N = 9 for CEF-specific responses).
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FIGURE 4 | Memory/effector phenotype analysis on expanded CD8+ T-cells from DT and ET individuals. (A) Distribution of effector/memory subsets in bulk CD8+
T-cells analyzed post-expansion. DT, Delayed treatment (N = 11 subjects, total 22 responses); ET, Early treatment (N = 13 subjects, total 26 responses). (B)
Distribution of effector/memory subsets in Nef-, p24-, and CEF-specific CD8+ T-cells, identified on the bases of cytokine production and/or degranulation capacity.
DT, Delayed treatment (N = 10 Nef-specific responses, N = 8 p24-specific responses, N = 5 CEF-specific responses); ET, Early treatment (N = 12 Nef-specific
responses, N = 12 p24-specific responses, N = 10 CEF-specific responses). In (A,B), analyses were performed with SPICE software. In bar graphs, the color code
shown at the bottom mirrors the one shown in the pies. Black dots represent DT subjects and gray dots represent ET subjects. Boxes extend from min to max,
horizontal bar within boxes represent median values. When analyzing global distribution (pies) permutation tests were applied, instead when analyzing bar graphs,
Student T-test were used. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.005. SCM, Stem cell memory; CM, Central memory; EM, Effector memory; TE, Terminal effector.
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significantly higher proportion of degranulating and/or cytokine-
producing cells compared to TTE in both groups (Figure S2B)
pointing to a rheostat-like function of PD-1 rather than being
merely a marker of cell exhaustion.
Overall, both at the bulk and HIV-specific compartments, ET
subjects showed a preservation of early differentiated cells (TSCM
and TCM), which was also represented as a higher proportion of
TSCM and TCM cells within the PD-1
+ compartment. DT subjects
showed a differentiated profile with increased representation of
cells with effector phenotype (TEM and TTE). PD-1 expression
was concentrated in HIV-specific CD8+ TEM cells.
Expanded CD8+ T-Cells From DT and ET
Subjects Were Highly Capable of Mediating
Antiviral Activity
The capacity of in vitro expanded CD8+ T-cells to exert
viral inhibition by cytolitic and non-cytolitic mechanisms was
evaluated by two different assays (see M&M and Figure 1).
First, the VIA assay (which measures the magnitude of the
overall CD8+ T-cell antiviral potency comprising both cytolytic
and non-cytolytic pathways) (39) was performed to evaluate
the ability of expanded cells (either expanded with Nef or p24
peptides) to suppress the replication of one lab-adapted HIV
strain (NL4-3) and three T/F primary strains (V4, V8, and V9).
A significant capacity to mediate viral inhibition was observed
both for Nef-specific and p24-specific cells from DT and ET
subjects toward all viruses assayed (Figure 6A). Within Nef-
specific CD8+ T-cells, no significant differences were found
between groups in their capacity to mediate VIA, although a
trend was evident toward DT individuals displaying a higher
capacity (p = 0.0616). In contrast, p24-specific CD8+ T-cells
fromDT subjects showed a significantly stronger antiviral activity
compared to p24-specific cells from ET subjects (p = 0.005).
No significant differences were observed when analyzing Nef-
specific and p24-specific cells within each study group. In
parallel, the VITAL assay (which depicts direct cytotoxicity)
was performed. Figure 6B shows dot-plots obtained from one
representative assay, which depicts specific progressive loss of
antigen-loaded CFSE+ target cells as effectors are added at
increasing ratios. Compiled data indicated that no significant
difference could be observed between DT and ET individuals
at any E:T ratio evaluated, regardless of CD8+ T-cell specificity
(Figure 6C). When performing an intragroup response analysis
(i.e., comparing Nef-specific vs. p24-specific CD8+ T-cells from
DT or ET subjects), no differences were found (Wilcoxon’s test
p > 0.05). Only a tendency toward Nef-specific CD8+ T-cells
was evidenced showing an improved capacity to mediate a direct
cytolytic activity compared to p24-specific CD8+ T-cells in both
groups.
Full Differentiation, Polyfunctionality, and
PD-1 Expression of CD8+ T-Cells Relate to
Antiviral Function in This Expanded Model
Thus, we sought to investigate the relationship between CD8+ T-
cell phenotype and functionality (in terms of cytokine production
and degranulation capacity) post in vitro expansion, and the
magnitude of antiviral activity measured by VIA and VITAL
assays. For this, results obtained with Nef- and p24-specific
effectors were merged, due to no intragroup differences (i.e.,
within DT or ET subjects). First, a potential association with
the results from the VIA assay was investigated. Activity against
all viruses was examined. Correlation analysis revealed that the
magnitude of VIA was inversely correlated with the proportion
of bulk CD8+ TSCM cells (r = −0.2634, p = 0.0054), bulk
CD8+ TCM cells (r = −0.2058, p = 0.031), and directly
with the proportion of bulk CD8+ TTE cells (r = 0.1878,
p = 0.0495). All correlations remained statistically significant
after adjusting for multiple comparisons (p = 0.0270, p =
0.0775, and p = 0.0825, respectively). Furthermore, an inverse
correlation with the proportion of HIV-specific CD8+ TSCM cells
was found (r = −0.2529, p = 0.0195, adjusted p = 0.0713;
Figure 7A). On the other hand, no significant correlations
were found when analyzing the capacity of cells to mediate
degranulation and/or secrete cytokines. Second, the magnitude
of VITAL assay, at 1:5 T:E ratio, was inversely correlated with
the proportion of HIV-specific CD8+ TSCM cells (r = −0.4677,
p = 0.0376, adjusted p = 0.0627), inversely with HIV-specific
CD8+ TCM cells (r = −0.7228, p = 0.0003, adjusted p =
0.015), and directly correlated with the proportion of HIV-
specific CD8+ TTE cells (r = 0.5035, p = 0.0280, adjusted p =
0.0627) (Figure 7B). Additionally, correlations between VITAL
magnitude and CD8+ T-cell functionality were also found: direct
correlations with the proportion of degranulating cells (r =
0.5065, p = 0.0162, adjusted p = 0.0432), IFN-γ-producing (r
= 0.563, p = 0.0064, adjusted p = 0.0259), CCL4-producing
(r = 0.5957, p = 0.0034, adjusted p = 0.0259), and TNF-α-
producing CD8+ T-cells (r = 0.5494, p = 0.0081, adjusted p
= 0.0259), as well as with proportions of polyfunctional cells
able to degranulate and secrete IFN-γ alone or plus one or two
extra functions, regardless of any particular one (r = 0.4652,
p = 0.0291, adjusted p = 0.0582; r = 0.5671, p = 0.0059,
adjusted p = 0.0259, r = 0.549, p = 0.0081, adjusted p = 0.0259,
respectively), and also tetrafunctional cells able to degranulate,
express IFN-γ and TNF-α plus 1 extra functions (r = 0.4767,
p = 0.0249, adjusted p = 0.0569) (Figure 7C). Finally, PD-1
expression within HIV-specific cells proved to directly correlate
with direct cytotoxicity (VITAL assay 1:5 ratio; r = 0.4861, p
= 0.0160, adjusted p = 0.032), the proportion of degranulating
cells (r = 0.699, p = 0.0012, adjusted p = 0.0063), IFN-γ-
producing CD8+ T-cells (r = 0.7647, p = 0.0002, adjusted p =
0.0014), CCL4-producing CD8+ T-cells (r = 0.7661, p = 0.0002,
adjusted p = 0.0014) and TNF-α producing CD8+ T-cells (r
= 0.8493, p < 0.0001, adjusted p = 0.0014). Interestingly, PD-
1 expression within HIV-specific cells also directly correlated
with the proportion of degranulating polyfunctional cells that
concomitantly secrete IFN-γ, TNF-α plus one extra function (r
= 0.6809, p = 0.0019, adjusted p = 0.008) (Figure 7D). Overall,
this data points toward the need to fully differentiate into an
effector phenotype to gain maximum antiviral activity in both
assays. VITAL assay better correlated with subsets of functions
containing degranulating cells, thus reflecting the nature of the
assay. Of note, correlations with the proportion of IFN-γ and
TNF-α-producing CD8+ T-cells might be driven by a high
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FIGURE 5 | PD-1 expression on expanded CD8+ T-cells from DT and ET individuals. (A) Post-expansion percentages of bulk and HIV-specific PD-1+ CD8+ T-cells.
Boxes extend from min to max. Horizontal bar within boxes represent the median. *p ≤ 0.05; ****p ≤ 0.0001 according to Wilcoxon’s test. (B) Distribution of
effector/memory phenotypes within bulk PD-1+ CD8+ T-cells analyzed post-expansion. Analysis was performed with SPICE software. In bar graphs, the color code
shown at the bottom mirrors the one shown in the pies. Black dots represent DT subjects and gray dots represent ET subjects. Boxes extend from min to max,
horizontal bar within boxes represent median values. When analyzing global distribution (pies) permutation tests were applied, instead when analyzing bar graphs,
Student T-test were used. *p ≤ 0.05; **p ≤ 0.01. DT, Delayed treatment (N = 11 subjects, 21 responses). ET, Early treatment (N = 13 subjects, 26 responses). SCM,
Stem cell memory; CM, Central memory; EM, Effector memory; TE, Terminal effector.
coexpression with CD107a/b+ cells. Interestingly, PD-1 appeared
as a marker of polyfunctional expanded cells able to mediate
direct cytolysis.
DISCUSSION
Combination antiretroviral treatment has largely improved
HIV+ individual’s quality of life and expectancy. Nevertheless,
it cannot eliminate the viral reservoir by itself, precluding
thus the cure of the infection. Many strategies have been
proposed to eradicate the viral reservoir. The success of some
of these strategies, such as the “shock and kill” approach,
will rely mainly on the ability of HIV-specific CD8+ T-cells
to clear reactivated infected cells. Nevertheless, our knowledge
regarding the quality of remaining CD8+ T-cell responses on-
cART is not accurate. Pivotal studies indicated that cART-
treated individuals retain CD8+ T-cells that, upon ex vivo
expansion, are able to exert antiviral activity in vitro, even against
reactivated cells (i.e., latently infected CD4+ T-cells exposed
to latency reversal agents) (57–59), although the depletion of
infected cells is not complete (60). Yet, the functional and
phenotypic characteristics needed to boost in the quest of
a functional cure are not thoroughly understood. Here, we
performed a comprehensive evaluation of the quality of in
vitro expanded CD8+ T-cells obtained from HIV+ subjects
who initiated cART at early (<4 month) or delayed (>4
month) time-points post-infection. Results indicated that (i)
Nef- and p24-specific T-cell responses could be expanded in
vitro, both in DT and ET subjects; (ii) expanded cells were
highly polyfunctional; (iii) after expansion, the memory/effector
differentiation profile was sharply skewed toward an effector
phenotype, although ET subjects showed preserved proportions
of TN, TSCM, and TCM subsets; (iv) expanded CD8
+ T-
cells were highly capable of mediating antiviral activity
and the magnitude of these activities were related to the
proportion of fully-differentiated effector cells as well as with
CD8+ T-cell functionality; (v) PD-1 expression in expanded
cells was mainly concentrated in HIV-specific TEM CD8
+
cells and correlated to cell polyfunctionality and cytolytic
activity.
Compiling evidence depicts the profound benefits that early
initiation of cART has on both virologic and immunologic
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FIGURE 6 | Capacity of in vitro expanded CD8+ T-cells to exert viral inhibition by cytolytic and non-cytolytic mechanisms. (A) In vitro viral inhibition assay (VIA)
mediated by Nef-specific (left panel) and p24-specific (right panel) CD8+ T-cells. VIA was expressed as the log10 of the proportion of p24 antigen lost when effector
CD8+ T-cells were present in the culture, compared to target cells (infected autologous CD4+ T-cells) alone. Dots represent individual subjects. The different viral
strains employed in the experiment are displayed in a different color. DT, Delayed treatment (N = 4 subjects, 14 Nef-specific responses and 15 p24-specific
responses); ET, Early treatment (N = 12 subjects, 40 Nef-specific responses and 41 p24-specific responses). (B) Dot-plots obtained in one representative VITAL
assay. At the 1:0 T:E ratio (far left panel), an even distribution of peptide-loaded (CFSE+PKH26−) targets and not-loaded targets (CFSE−PKH26+) targets is
observed. From left to right, increasing ratios of effectors (1:1, 1:1 adjusted [i.e., 1:1 ratio adjusted to proportion of specific CD8+ T-cell effectors as determined by
intracellular staining and flow cytometry], 1:5 and 1:10) are shown and the concomitant loss of antigen-loaded targets is observed. (C) Percentage of specific lysis
exerted by Nef-specific (left panel) and p24-specific (right panel) CD8+ T-cells, as determined by the VITAL assay. Results for DT and ET subjects are shown at the
different T:E ratios evaluated. DT, Delayed treatment (N = 7 subjects for Nef-specific responses and N = 6 subjects for p24-specific responses). ET, Early treatment (N
= 10 subjects, both for Nef- and p24-specific responses). Black dots represent DT subjects and gray dots represent ET subjects. In (A,C), boxes extend from min to
max values. Horizontal lines within boxes represent the median values. In (A), intergroup differences were analyzed using Mann-Whitney test; **p < 0.01.
parameters in infected individuals (26, 27, 31, 47). Longer
antigen persistence was shown to be deleterious on HIV-specific
CD8+ T-cells, resulting in an exhausted and hyperactivated
immune response (27, 61). Furthermore, the latent reservoir
is not only larger in size but also altered in its composition,
possibly containing variants resistant to dominant CD8+ T-cell
responses, rendering immune eradication therapies less efficient
in individuals initiating cART during chronic infection (58).
So far, few works have studied the differences in breadth and
magnitude of CD8+ T-cell responses arising from starting cART
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FIGURE 7 | Correlation analyses between antiviral activity versus cell phenotype and functionality of expanded CD8+ T-cells. (A) Correlations between VIA magnitude
(evaluated against all viruses and merging data from Nef-specific and p24-specific effectors) and bulk and HIV-specific CD8+ T-cell memory phenotype. Square dots
represent DT subjects and round dots represent ET subjects. The different viral strains employed in the VIA experiment are displayed in a different color, matching the
color code showed in Figure 6 A. (B,C) Correlations between VITAL magnitude and the proportions of HIV-specific CD8+ T-cell memory phenotype (B), and the
proportions of CD8+ T-cell functionality (C). (D) Correlations between the percentage of PD-1 expressing HIV-specific CD8+ T-cells and cell functionality. (B–D) Black
dots represent DT subjects and gray dots represent ET subjects. r and p values correspond to Spearman’s correlations.
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at different time-points after infection (54, 62, 63), but no
evaluation has been focused on how those differences impact on
the final antiviral activity, an important issue to be addressed
when assessing functional cure strategies. In this context, we
aimed to assess whether the moment of cART initiation (relative
to the presumed date of infection) has an impact on post-
expansion HIV-specific CD8+ T-cell responses.
Because CD8+ T-cell responses in subjects on cART are
dramatically diminished (15–20), an in vitro cell expansion
protocol was implemented. Several and diverse works have
proven its utility in boosting HIV-specific responses to optimal
activity (23, 40, 54, 57–59, 64–67). This work analyzed HIV-
specific CD8+ T-cell responses against Gag andNef peptide pools
based on a number of reasons: (1) during acute infection, Nef
is the immunodominant target (68–70), though the response
broadens afterwards to epitopes within other viral proteins
including Gag (71–75), (2) higher frequencies of CD8+ T-cells
with polyfunctional responses to Gag and Nef were associated
with lower viral set-points (76), (3) Gag-specific CD8+ T-cell
responses were associated with virus control in different settings
(72–74, 77); particularly, early anti-Gag immunodominance
was associated with improved antiviral activity and also with
lower rate of disease progression (13); (4) expandable Gag
responses were associated with strong antiviral activity and
lower residual viral loads in Elite Controllers (40, 66); (5) Nef
protein is detectable in PBMCs from subjects under cART
(78) and (6) CD4+ T-cells from individuals on prolonged
therapy contain “defective” proviral sequences that are able to
express Nef (79). Despite being the CD8+ T-cell response very
low and at times almost undetectable before stimulation, we
were able to specifically and significantly expand it in both
groups of individuals. However, DT subjects displayed a more
homogeneous response, in terms of specificity, than ET subjects,
for whom the post-expansion response was narrower. This could
likely occur due to a longer period of antigen stimulation, which
would have allowed CD8+ T-cells from DT to develop into
a broader-spectrum of specificities to different viral antigens.
In consonance with the results obtained by Deng et al. a
broader CD8+ T-cell response would be favorable when the
elimination of reactivated viruses is required (58). Nevertheless, it
is worth noting that anti-Nef and anti-p24 responses were equally
expandable in both groups.
Early reports comparing the capacity of CD8+ T-cells
to degranulate and secrete multiple soluble mediators upon
stimulation, between individuals with progressive vs. long-term
nonprogressive HIV infection, have suggested that CD8+ T-
cell polyfunctionality would be a functional correlate of virus
control (76, 80). Later, it was shown that polyfunctionality does
not necessarily correlate with disease progression (13). Instead,
lack of T-cell polyfunctionality would be the consequence of
constant antigen stimulation during viremic chronic infection,
which ultimately may lead to cell exhaustion and functional
impairment (81, 82). In any case, CD8+ T-cell polyfunctionality
relates to a beneficial response. Here, a significant proportion of
peptide-expanded CD8+ T-cells presented the ability to mediate
different and simultaneous functions. In this line, several reports
have evidenced the significant presence of polyfunctional cells
upon expansion with specific peptides (40, 48). Particularly,
Ndhlovu et al. (40) showed that, after expansion with a similar
protocol to the one used here, Elite controllers had significantly
higher frequencies of polyfunctional cells compared to a group of
chronically infected subjects on cART. Contrary to the findings
of Ndhlovu et al. we did not observe differences between study
groups, i.e., polyfunctionality was equally evident in DT and ET
subjects. One point to be considered is that DT and ET groups
are less polar than Elite controllers and chronics on cART. Thus,
more subtle differences might exist between DT and ET which
could not be evidenced here. Regarding time to cART initiation,
a similar study also indicated that it did not impact CD8+ T-cell
polyfunctionality profile, although evaluated directly ex vivo (54).
CD8+ T-cells follow a progressive pathway of differentiation
from naïve T-cells into different memory/effector subsets.
Each subset is characterized by self-renewal, proliferative and
functional attributes (83).Memory CD8+ T-cell differentiation in
progressive HIV infection is severely skewed, reflecting improper
terminal differentiation of effector cells (14, 84, 85). Interestingly,
the early deterioration of CD8+ T-cell differentiation pathway
was directly associated with disease progression (14, 86), while
effective cART seems not to restore this phenomenon completely
(65). Here, CD8+ T-cell memory/effector differentiation was
evaluated post-expansion in cells from DT and ET subjects. In
this condition of strong antigen triggering and cytokine-driven
proliferation signaling, a considerable extent of differentiation
to effector phenotypes was expected. However, this was not
equally represented by the two study groups included in
this work: ET subjects had increased proportions of TN,
TSCM, and TCM upon expansion. Initially, this could have
been considered as an advantage since less differentiated cells
with improved proliferative and self-renewal capacities were
preserved. However, as will be later discussed, it inversely
correlated with antiviral function. CD8+ TSCM cells have been
described as a subset of antigen-experienced cells that retain a
core of genes expressed by TN cells, and also display superior
ability to proliferate homeostatically and persist in the long term
(83). Recently, it has been reported that HIV+ subjects receiving
cART have higher proportions of CD8+ TSCM cells and that
this proportion even increases as time on cART extends (87).
Since DT and ET subjects have a similar median time on cART
at the moment of sampling, it would be interesting to evaluate
if a higher representation of CD8+ TSCM cells after expansion
could be reflecting an increase in the frequency of TSCM cells
before expansion. This in turn, would be a consequence of
the earliest cART initiation. For regimens of adoptive cell
transfer, widely explored in the field of cancer and Epstein-
Barr virus–associated malignancies, it is known that CD8+ T-cell
differentiation widely affects the anti-tumoral response: although
effector memory cells have fully functional differentiation, the
diminished proliferative capacity severely compromises the
success of the adoptive transfer because the effect is transient.
Thus, strategies for limiting ex vivo differentiation but retaining
functional differentiation are being evaluated (88). The same
reasoning could apply in this context: ET subjects harbor the
advantage of a preserved TSCM subset but strategies to potentiate
their antiviral activity should be explored.
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Apart from memory/effector phenotype, the expression of
PD-1 was investigated post-expansion. PD-1 is an inhibitory
coreceptor that is involved in the fine-tuned regulation of the
threshold of antigen responses of T and B cells. It is endowed with
unique modulatory functions where its presence/absence matters
but also its expression level is crucial (89, 90). During chronic
viral infections, extremely high and persistent PD-1 expression
has been found in T cells. This PD-1high phenotype has been
consistently associated with a state of cellular exhaustion in the
context of different persistent viral infections, including HIV
(14, 55, 56, 89, 91, 92). In this study, PD-1 expression in expanded
CD8+ T-cells was low compared to other reports measuring PD-
1 expression directly ex vivo, as already mentioned. This could
be the result of PD-1 down-modulation or death of PD-1+ cells
during expansion. The latter would be in consonance with the
notion that exhausted PD-1+ cells show decreased telomerase
activity and telomere lengths rendering them more susceptible
to cell death (93, 94). Expanded PD-1+ cells were concentrated
in the HIV-specific compartment, particularly within CD8+ TEM
and TTE cells. In addition, positive correlations were found
between PD-1 expression on expanded HIV-specific cells and
CD8+ T-cell functionality. This is in line with data provided
by Hokey et al., who found high PD-1 expression on cells with
activated memory and effector phenotypes despite decreased
telomere lengths, suggesting PD-1 could play a costimulatory
role in CD8+ T-cell populations (95). Moreover, a recent
report showed that tumor-reactive CD8+ T-cells that persist
after adoptive cell-transfer therapy, and associate with tumor
regression, are mostly polyfunctional and simultaneously express
high levels of PD-1 (96). This data highlights the fact that the PD-
1 role in the context of viral reactivation needs further research.
Many studies have already proven the benefits of PD-1 signaling
inhibition by anti-PD-1L (anti-PD-1 ligand] at the moment of
CD8+ T cell stimulation, (93, 97). Combination therapies that
stimulate and simultaneously modulate the specific immune
response (through PD-1 blocking for instance) are believed to be
the optimal approaches for future therapeutic schemes (98, 99).
Then, we aimed to analyze whether CD8+ T-cells quality
and phenotype would have an impact on the global capacity to
mediate viral inhibition. To attain this, two different approaches
were used. VIA is a versatile technique that allowed us to
investigate CD8+ T-cell-mediated inhibition of viral replication
of four different virus strains, three HIV-1 primary isolates and
a laboratory strain. Even though it provides a global picture
of the antiviral response, it cannot discriminate if cytotoxicity
plays a relevant antiviral role in this expansion model. To
assess this aspect, Herman’s VITAL assay was implemented. This
method particularly evaluates the direct cytotoxicity, requiring
cell-to-cell contact between peptide-loaded target cells and
effectors. Thus, this was carried out concomitantly with VIA
to assess the contribution of cytolytic mechanisms to the
global antiviral response. We considered relevant to perform
such a discrimination because in a context of functional
cure, strong cytolytic activity would be preferred over non-
cytolytic mechanisms to eliminate reactivated cells (100). In
this fashion, these experiments provide complementary data,
granting a larger picture of the immune response. Here, both
Nef- and p24-specific cells from DT and ET individuals were
able to mediate VIA against the broad repertoire of viruses
assayed, including clinically relevant viral strains. HIV-specific
cells from DT group were prone to display greater inhibitory
activity than ET but it was only statistically different from p24-
specific cells. Bulk CD8+ T-cell differentiation level correlated
with VIA magnitude, stating that complete differentiation was
needed to be achieved in order to mediate viral inhibition. We
have already proven that terminal memory differentiation was
needed to exert optimal antiviral activity in subjects off-cART
and measured directly ex vivo (14). Here, this association was
maintained even after expansion and in subjects on cART. This
is consistent with reports that proved effector memory T-cells
efficiency at controlling new infections because they are endowed
with more immediate effector functions (27, 101). For VITAL
assay, no differences were found between groups. Furthermore,
VITAL magnitude correlated with a higher proportion of HIV-
specific terminal effector cells. We also found that cells able
to degranulate and secrete IFNγ or TNFα, either as unique
functions or combined, exerted a greater cytolityc activity. In
this line, it has been shown that CD107a/b surface expression
was associated with the capacity of antigen-specific CD8+ T-
cells to eliminate infected cells as observed in VIA assays (13,
102). Additionally, CCL4 has been shown to interfere with
HIV infection by blocking the binding to CCR5 coreceptor
and has been associated with higher VIA magnitude (102). In
our model, no differences were found in the total percentage
of CCL4-expressing CD8+ T-cells between groups, which is
consistent with the lack of difference in VIA magnitude. To
date, no reports associated VITAL assays with the level of
degranulation post-expansion in HIV-specific cells, representing
a novel finding. Of note, most correlations found for VITAL
assay were driven by results obtained for Nef-specific responses.
Moreover, a tendency toward Nef-specific cells able to mediate
stronger direct cytotoxicity was evidenced. Given that CD4+
T-cells from HIV+ subjects on treatment upregulate HIV-1
mRNA within 1 h of stimulation and produce extracellular virus
as early as six-h poststimulation, CD8+ T-cells that recognize
specifically early gene products, such as Nef, would be most
beneficial in functional cure approaches. Additionally, they
would effectively kill reactivated cells before viral spread and Nef-
mediated MHC-downmodulation (67). Indeed, recent findings
indicated that ongoing Nef-expression in treated subjects is
associated with the maintenance of Nef-specific CD8+ T-cells
(28). Not only our results suggest that direct cytotoxicity was
mediated more efficiently by Nef-specific CD8+ T-cells, but
also, for the reasons above stated, it would be an important
target to boost in functional cure approaches and vaccine
formulations.
Overall, this is a novel comprehensive study evaluating the
quality of in vitro expanded CD8+ T-cells from DT and ET
HIV+ subjects with relevant implication in the design and
evaluation of functional cure strategies relying on CD8+ T-cell-
mediated killing among others. Limitations of this study include,
but might not be restricted to: (i) the use of a strong and
prolonged stimulation protocol for T-cell expansion might mask
subtle inter-group differences, for instance as a consequence
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of activation-induced cell death of certain cell subsets and
survival of others common to both groups, thus we cannot
exclude the possibility that with alternative expansion protocols
(such as by using IL-7 or IL-15) differences may arise; (ii)
identification of HIV-specific cells by combining molecules
with the same fluorochrome leads to the underestimation of
the specific response which might be mistakenly considered
within the bulk compartment; (iii) production of perforins and
granzymes, which were already described as key components
of CD8+ T-cell antiviral function, were not measured, and
thus not accounted, for depicting CD8+ T-cell quality; (iv)
DT group is highly heterogenous which might potentially
lead to data misinterpretation; (v) ET subjects might have
initiated treatment even after seroconversion so they do not
represent really early treated subjects such as those defined
in other cohorts (27). This last point might instead be
interpreted as an advantage in terms of potential translation
of the results to the every-day practice. Detection of an
acutely infected subject is extremely unusual, being mostly
diagnosed at late Fiebig stages (IV to VI). Therefore, the
scenario presented here would better approximate to a real
context.
In sum, low frequency of HIV-specific CD8+ T-cells
from subjects on-ART for at least 1 year were readily
expandable in vitro and retained antiviral functions. Minor
qualitative differences were observed in expandable CD8+ T-cell
responses between DT and ET subjects, mostly related to the
memory/effector differentiation profile. Thus, the initiation of
cART before the viral set-point did not represent a major benefit
in terms of post-expansion CD8+ T-cell quality in our model.
In other words, having started cART during chronic infection
would not represent an obstacle to undergo immunomodulatory
approaches. Studies aimed at determining how the quality of the
pre-cART response relates to the post-expansion scenario and
how all these parameters relate to the viral reservoir are being
conducted. Although we showed here that in vitro expansion
results in a fully antiviral functional response, it remains to be
elucidated if this kind of responses (with the proper specificity
and functionality), can be elicited in vivo (through therapeutic
vaccination, for instance) or if an adoptive transfer strategy
would be the best option to achieve a functional cure for HIV.
Additionally, the inclusion of immunomodulators (immune
checkpoint inhibitors and/or agonist of stimulatory pathways)
should be considered to overcome the intrinsic immune damage
caused by the infection in each particular subjects, leading to
the development of tailor-made regimens. In any case, these
results add important information to rationally design and/or
evaluate future strategies to modulate not only anti-HIV T-cell
responses but also immune responses toward other persistent
pathogens.
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Figure S1 | Gating strategy used for the identification of the studied cellular
populations, by flow cytometry. (A) To study CD8+ T-cell polyfunctionality, initial
gating was performed on a forward scatter area (FSC-A) vs. FSC-height (FSC-H)
plot to remove doublets. Dead cells were then excluded on the bases of Zombie
NIR fluorescence. Then, gating was performed on CD14/CD19 negative cells in
order to exclude monocytes and B lymphocytes, and then small lymphocytes were
selected in FSC vs. side scatter (SSC) plot. Subsequently, CD3+ cells were gated
in a CD3 vs. SSH dot plot, and then a CD8 vs. CD4 dot-plot was constructed to
identify CD8+ events. To study CD8+ T-cell polyfunctionality, plots were derived
from the CD8+ gate to study each particular function: degranulation (evidenced
as CD107a/b mobilization) and production of IFN-γ, IL-2, CCL4, and TNF-α. Cells
capable of exerting multiple functions simultaneously (degranulating and/or
secreting multiple cytokines; 2, 3, 4, or 5 functions) were identified using the
Boolean gating strategy available at FlowJo v10 software. (B) For the phenotype
panel, the initial gating strategy was identical to the polyfunctionality panel
up-to-the point of CD8 vs. CD4 plot. There, CD8+ events were gated to define
bulk CD8+ T-cells and a CD8 vs. FITC plot was derived to identify HIV-specific
CD8+ T-cells (defined as the ones degranulating and/or expressing cytokines, all
stained in FITC). Subsequent analyses were performed on both populations as
shown by overlaid dot-plots and overlaid histograms. To analyze the distribution of
the different phenotype subsets, CD45RO vs. CCR7 density plots were
constructed to identify central memory T-cells (TCM, CCR7
+/CD45RO+), effector
memory T-cells (TEM, CCR7
−/CD45RO+) and terminal effector T-cells (TTE,
CCR7−/CD45RO−). CD95 expression was analyzed within the CD45RO−CCR7+
cells thus defining naïve T-cells (TN, CCR7
+/CD45RO−/CD95−) and stem-cell
memory T-cells (TSCM, CCR7
+/CD45RO−/CD95+). Additionally, PD-1 expression
was evaluated. In (A,B) illustration data represent cells derived from one
representative subject, stimulated for 14 days with the HIV Nef peptide pool.
Figure S2 | (A) Proportion of PD-1+ cells observed post-expansion on bulk
CD8+ TEM and TTE cells from DT and ET individuals. (B) Proportion of
HIV-specific cells (either Nef-specific or p24-specific) cells, identified on the bases
of cytokine production and/or degranulation capacity, observed post-expansion
on CD8+ TEM and TTE cells from DT and ET individuals. In (A,B), boxes extend
from min to max. Horizontal bar within boxes represent the median. ∗∗∗∗p ≤
0.0001 according to Wilcoxon’s test.
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